Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Inclusion Criteria: * Diagnosis of myelofibrosis, either PMF, PPV or PET MF * Palpable splenomegaly ≥ 5cm * May have been previously treated with either panobinostat or ruxolitinib (unless discontinued for clinically relevant toxicities) * Acceptable lab ranges for all organ systems * Specifically: Platelet count \> 100,000 not reached with the aide of transfusions * Blast count \< 10% at screening * ECOG ≤ 2 * Must be able to discontinue all drugs being used to treat MF at least 7 days prior to starting study drug Exclusion Criteria: * Active malignancy * Clinically significant heart disease * Splenic irradiation within 12 months of starting study drug * Need for ongoing systemic anticoagulation with the exception of Aspirin \< 150mg/day or Low Molecular Weight Heparin * History of platelet dysfunction or bleeding disorder in the 6 months prior to screening * Patient is at risk for spontaneous bleeding * Willing and/or eligible for stem-cell transplantation * Impairment of gastro-intestinal function that may impact the absorption of study treatment * Unwilling to use highly effective methods of contraception during dosing and for 13 weeks (female participants) or for 6 months (male participants and their female partners) after stopping study treatment